INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Avalanche Biotechnologies, Inc. (AAVL) to Contact the Firm
NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, has been appointed to serve as Lead Counsel in the consolidated class action captioned In re Avalanche Biotechnologies, Inc., Sec. Litig., Case No. 3:15-cv-03185-JD.
If you purchased shares pursuant to Avalanche Biotechnologies, Inc.’s (“Avalanche”) (NASDAQ:AAVL) initial public offering on or about July 31, 2014, pursuant to Avalanche’s secondary offering on or about January 13, 2015, and/or in the open market between July 31, 2014 and June 15, 2015, both dates inclusive, please contact the firm to discuss this matter with us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. For more information, you may visit the firm’s website at www.faruqilaw.com/AAVL.
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. rgonnello@faruqilaw.com Telephone: (877) 247-4292 or (212) 983-9330
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
